Another clinical trial (93) investigating transformative immunotherapy found that, following 3 cycles of induction therapy with a PD-L1/TGF-β bispecific antibody (with or without chemotherapy), 25.2% of patients (27/107) with unresectable locally advanced NSCLC were successfully converted to a resectable status. Here, CD274 is linked to non-small cell lung carcinoma.